A. Khan

Borato-1,2-diaminocyclohexane platinum (II), a novel anti-tumor drug.

A. Dibas, J. Howard, S. Anwar, 2000, Biochemical and biophysical research communications.

Durable response of metastatic endometrial carcinoma to treatment with fulvestrant (Faslodex) after prior progestin and anastrozole therapy.

M. Hoffman, A. Khan, 2006, Gynecologic oncology.

Cervical sarcoma botryoides and ovarian Sertoli-Leydig cell tumor.

J. Scurry, I. Macisaac, R. Planner, 1997, Gynecologic oncology.

Dosimetry and Gastrointestinal Toxicity Relationships in a Phase II Trial of Pelvic Lymph Node Radiotherapy in Advanced Localised Prostate Cancer

D. Dearnaley, S. Gulliford, K. Thomas, 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

TLR8 gene polymorphism and association in bacterial load in southern Punjab of Pakistan: an association study with pulmonary tuberculosis

S. Ahmad, U. Ashfaq, M. Ali, 2015, International journal of immunogenetics.

A rare case of vomiting: fourth ventricular B-cell lymphoma

S. McCartney, S. Bloom, A. Khan, 2009, Journal of Neuro-Oncology.

Hormone therapy for radiorecurrent prostate cancer

H. Payne, S. Chowdhury, R. Davda, 2013, World Journal of Urology.

A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.

T. Hickish, A. Wotherspoon, D. Cunningham, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Incidence of triple negative breast cancer phenotype in a predominantly Hispanic cohort.

Z. Mulla, B. Rajabi, Y. Tovar, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

350P Rheumatologic immune related adverse events (irAEs) secondary to immune checkpoint inhibitor (ICI) therapy: A Western Australia experience

M. Khattak, H. Martin, A. Khan, 2020 .